

Reig Jofre reinforces the area of specialised-technology products

APPOINTMENT OF FREDERIC DINGEON AS HEAD OF THE ANTIBIOTICS DEVELOPMENT AND PRODUCTION BUSINESS UNIT

- Reig Jofre reinforces the area of specialised-technology products, spearhead of the company's international development.
- This appointment is part of Reig Jofre's five-year strategic plan, by which the company will invest to increase production capacity in key areas.
- As already disclosed, after closing 2014 with turnover of € 152.5 M and EBITDA of € 15 M, Reig Jofre estimates organic growth to set sales at € 200 M and EBITDA at € 25 M in 2019.

Barcelona, November 10, 2015. The pharmaceutical company Reig Jofre has reinforced the area of specialized-technology products with the appointment of Frederic Dingeon as head of the development and production business unit of beta-lactam antibiotics, located in Toledo (Spain).

Frederic Dingeon, BA in Biological and Medical Sciences and PhD in Pharmacy, both from the University of Lyon (France), has also a Master's Degree in International Industrial Management from the HEC Business School in Paris (France).

Frederic Dingeon joins Reig Jofre with over fifteen years of track record in the pharmaceutical industry and international experience in project management of new industrial plants, galenical and analytical development, product launch and transfers, plant management and technical management at several international pharmaceutical companies as Merck, Sanofi and Servier.

In the antibiotics unit, Frederic Dungeon will be at the head of 280 of the total 820 employees that make up Reig Jofre.



Reig Jofre's business is divided into two major areas: a main one for the marketing and manufacture of own developments (RJF Pharma, approximately 78% of 2014 sales) and another for specialised contract development and manufacturing for other companies (RJF CDMO, 22% of 2014 sales).

Specialized-technology products (beta-lactam antibiotics and injectable) accounted for 54% of turnover of RJF Pharma in 2014, being traditionally Reig Jofre's spearhead in its international development due to its strong positioning as a leading developer, both for own products and for other international pharmaceutical companies. Reig Jofre is present in over 52 countries on five continents with this category, either through direct sales in seven markets or through partnerships with over one hundred licensees and/or distributors.

In Toledo (Spain), Reig Jofre has two independent manufacturing plants specialized in beta-lactam antibiotics: one for penicillin antibiotics in all dosage forms: (vials with sterile powder, oral dosages, sachets and syrups) and another for cephalosporin antibiotics in vials with sterile powder.

The company also has a development and manufacturing plant of injectable forms, oral- solids and semisolids in Barcelona (Spain) and another for topical dermatological products in Malmö (Sweden).

The appointment of Frederic Dineon is part of Reig Jofre's five-year strategic plan, by which the company estimates organic growth of 31% to set turnover at 200 million euros in 2019. To achieve these objectives, Reig Jofre estimates, among others, investments amounting to 8 million euros to expand production capacity to meet increasing demand.

Reig Jofre, which is listed on the Spanish stock market as a result of its merger with Natraceutical in December 2014 and has very low debt ratios, recently announced its will to combine organic growth with acquisitions to strengthen both international presence and RJF Pharma division.

Receive Reig Jofre's news by registering in the company's **subscription center** of the new corporate website: **www.reigjofre.com**

About Reig Jofre

After the merger between Laboratorio Reig Jofre and Natraceutical, the new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the marketing and manufacture of own developments (RJF Pharma, approximately 78% of sales in 2014) and one of specialized contract development and manufacturing (RJF CDMO, 22% of sales in 2014). At its core



activity, the company focuses on the development of specialised-technology products (antibiotics and injectable); therapeutic-specialty products in the areas of dermatology, gynaecology and respiratory; and nutritional supplements and consumer healthcare. The company directs its R&D to develop new indications and/or dosage forms of known active principles, generic medicines with a special focus on beta-lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and nutritional supplements as well as the development of new innovative molecules in partnership with start-ups and research centres.

Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 63,214,220.

For further information

Investors and analysts

Gloria Folch
Head of Investor Relations
REIG JOFRE
Tel. +34 93 480 67 10 – ext. 1241
gloria.folch@reigjofre.com

Media

Ricardo Franco
ATREVIA
Tel. +34 93 419 06 30
rfranco@atrevia.es